Clinical Evidence Library · Article 04
More laboratory terms can create more anxiety
Once people begin reading about vitamin D, they may encounter total 25(OH)D, free 25(OH)D, and parathyroid hormone (PTH). It is easy to conclude that a single familiar marker is suddenly “not enough,” or that everyone needs to track every possible number. That is not what the evidence says.
The useful goal is not to turn laboratory terminology into anxiety. It is to understand that different markers can help researchers ask different questions.
Total value, free value, and PTH are not rivals
Total 25(OH)D broadly refers to the overall amount of 25(OH)D measured in blood. Free 25(OH)D refers to the fraction not bound to carrier proteins. PTH is associated with calcium-phosphorus metabolism and vitamin D status. Each can contribute a different piece of information; none should be turned into a universal consumer obsession.
Calcifediol showed different responses in total and free markers
Shieh and colleagues randomized 35 adults with baseline 25(OH)D below 20 ng/mL to vitamin D3 at 60 μg/day or calcifediol at 20 μg/day for 16 weeks. The calcifediol group showed larger increases in total and free 25(OH)D than the D3 group. The study also explored relationships between these markers and PTH.
The study did not establish that free 25(OH)D is universally “better” than total 25(OH)D. It showed that, in this specific comparison, calcifediol and vitamin D3 had different observed effects across several vitamin D-related blood markers.
In vitamin D supplementation, form is more than a technical word on the panel
BUBBFOREST Calcifediol Vitamin D3 provides calcifediol rather than conventional vitamin D3. That is worth explaining not because “calcifediol” sounds more advanced, but because randomized research has observed distinct responses to this form in total and free 25(OH)D measurements.
The product’s central value can be stated plainly: it is a calcifediol-form vitamin D supplement. It offers an ingredient form with a human clinical research background, without claiming to interpret a test report or guarantee how any one marker will change.
BUBBFOREST × dsm-firmenich Partnership | ampli-D® Ingredient Clinical Evidence BUBBFOREST Calcifediol Vitamin D3 is developed with dsm-firmenich and uses ampli-D® calcifediol. Shieh’s randomized comparison matters because it examined not only total 25(OH)D, but also free 25(OH)D and PTH-related patterns. That gives the calcifediol ingredient a more substantive human-research context than a single promotional phrase. dsm-firmenich cites more than 15 human studies for ampli-D®. The evidence is ingredient-level context, however—not a guarantee that the BUBBFOREST finished product will improve every laboratory measure.
Summary Conclusion
Whether to test, which markers to test, and when to retest should depend on individual context and professional guidance. Instead of being pulled into “total versus free” anxiety, start with the basics: serum 25(OH)D is commonly used, supplement form can influence study outcomes, and a single number is not a complete health answer.
BUBBFOREST Calcifediol Vitamin D3 can be understood as a daily calcifediol vitamin D option—not as a laboratory-result reversal plan. The study was small, single-center, and did not compare equal microgram doses; it should not be generalized to all people or all products.
Reference: Shieh A, et al. Effects of Cholecalciferol vs Calcifediol on Total and Free 25-Hydroxyvitamin D and Parathyroid Hormone. 2017.
Educational content only. The research discussed concerns calcifediol and the ampli-D® ingredient evidence pathway. It is not a clinical trial of the finished BUBBFOREST product and does not guarantee an individual outcome. Consult a qualified healthcare professional for personal medical advice.